Skip to main content

Advertisement

SpringerLink
Log in

Statin use in the metabolic syndrome

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The metabolic syndrome is a condition associated with obesity, insulin resistance, hypertension, dyslipidemia, hypercoagulability, and chronic inflammation, all of which increase the risk of cardiovascular disease (CVD). The Third National Cholesterol Education Program Adult Treatment Panel extensively discussed the metabolic syndrome because it is a major health issue in the United States due to the national epidemic of obesity. Statins cause significant CVD risk reduction in patients with the metabolic syndrome by alterations in lipid levels and possibly by decreasing inflammation. Because of the increased CVD risk associated with the metabolic syndrome and extensive clinical trial evidence documenting reduction of CVD risk with statin treatment, all patients with the metabolic syndrome should be evaluated as candidates for statin treatment as part of a multidisciplinary approach to reduce CVD risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

  2. Reaven GM: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998, 15:539–553.

    Article  CAS  Google Scholar 

  4. Comment on the provisional report from the WHO consultation. Diabetic Med 1999, 16:442–443.

  5. American Heart Association: Heart Disease and Stroke Statistics—2004 Update. Dallas, TX: American Heart Association; 2003.

    Google Scholar 

  6. Moller DE, Flier JS: Insulin resistance—mechanisms, syndromes, and implications. N Engl J Med 1991, 325:938–948.

    Article  PubMed  CAS  Google Scholar 

  7. Kahn CR, Rosenthal AS: Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979, 2:283–295.

    PubMed  CAS  Google Scholar 

  8. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002, 288:1723–1727.

    Article  PubMed  Google Scholar 

  9. Kissebah AH, Vydelingum N, Murray R, et al.: Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982, 54:254–260.

    PubMed  CAS  Google Scholar 

  10. Chen KW, Boyko EJ, Bergstrom RW, et al.: Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995, 18:747–753.

    Article  PubMed  CAS  Google Scholar 

  11. Carr DB, Utzschneider KM, Hull RL, et al.: Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004, 53:2087–2094.

    Article  PubMed  CAS  Google Scholar 

  12. Nyholm B, Nielsen MF, Kristensen K, et al.: Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients. Eur J Endocrinol 2004, 150:207–214.

    Article  PubMed  CAS  Google Scholar 

  13. Kelley DE, Kuller LH, McKolanis TM, et al.: Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004, 27:33–40.

    Article  PubMed  CAS  Google Scholar 

  14. Maegawa H, Shigeta Y, Egawa K, Kobayashi M: Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in nonobese subjects with NIDDM. Diabetes 1991, 40:815–819.

    Article  PubMed  CAS  Google Scholar 

  15. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.

    Article  PubMed  CAS  Google Scholar 

  16. Juge-Aubry CE, Somm E, Chicheportiche R, et al.: Regulatory effects of interleukin (IL)-1, interferon-beta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue. J Clin Endocrinol Metab 2004, 89:2652–2658.

    Article  PubMed  CAS  Google Scholar 

  17. Arnush M, Heitmeier MR, Scarim AL, et al.: IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998, 102:516–526.

    PubMed  CAS  Google Scholar 

  18. Bloomgarden ZT: Inflammation and insulin resistance. Diabetes Care 2003, 26:1922–1926.

    Article  PubMed  Google Scholar 

  19. Mooradian AD: Obesity: a rational target for managing diabetes mellitus. Growth Hormone IGF Res 2001, 11 (Suppl A): S79-S83.

    Article  Google Scholar 

  20. Saleh J, Sniderman AD, Cianflone K: Regulation of plasma fatty acid metabolism. Clin Chim Acta 1999, 286:163–180.

    Article  PubMed  CAS  Google Scholar 

  21. Kopelman PG, Albon L: Obesity, non-insulin-dependent diabetes mellitus and the metabolic syndrome. Br Med Bull 1997, 53:322–340.

    PubMed  CAS  Google Scholar 

  22. Lam TK, Carpentier A, Lewis GF, et al.: Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003, 284:E863-E873.

    PubMed  CAS  Google Scholar 

  23. Boden G, Chen X: Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995, 96:1261–1268.

    Article  PubMed  CAS  Google Scholar 

  24. Randle PJ, Garland PB, Hales CN, Newsholme EA: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785–789.

    Article  PubMed  CAS  Google Scholar 

  25. Borkman M, Storlien LH, Pan DA, et al.: The relation between insulin sensitivity and the fatty-acid composition of skeletal-muscle phospholipids. N Engl J Med 1993, 328:238–244.

    Article  PubMed  CAS  Google Scholar 

  26. Shulman GI: Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology 2004, 19:183–190.

    Article  PubMed  CAS  Google Scholar 

  27. Cline GW, Petersen KF, Krssak M, et al.: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 1999, 341:240–246.

    Article  PubMed  CAS  Google Scholar 

  28. Austin MA, Rodriguez BL, McKnight B, et al.: Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000, 86:412–416.

    Article  PubMed  CAS  Google Scholar 

  29. Buring JE, O’Connor GT, Goldhaber SZ, et al.: Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992, 85:22–29.

    PubMed  CAS  Google Scholar 

  30. Singer DE, Nathan DM, Anderson KM, et al.: Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992, 41:202–208.

    Article  PubMed  CAS  Google Scholar 

  31. Miura K, Daviglus ML, Dyer AR, et al.: Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med 2001, 161:1501–1508.

    Article  PubMed  CAS  Google Scholar 

  32. Lewington S, Clarke R, Qizilbash N, et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903–1913.

    Article  PubMed  Google Scholar 

  33. Downs JR, Clearfield M, Weis, S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  34. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.

  35. Girman CJ, Rhodes T, Mercuri M, et al.: The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136–141.

    Article  PubMed  CAS  Google Scholar 

  36. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709–2716.

    Article  PubMed  Google Scholar 

  37. Malik S, Wong ND, Franklin SS, et al.: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.

    Article  PubMed  Google Scholar 

  38. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993, 269:3015–3023.

  39. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.

    Article  PubMed  Google Scholar 

  40. Ballantyne CM, Olsson AG, Cook TJ, et al.: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046–3051.

    PubMed  CAS  Google Scholar 

  41. Ballantyne CM, Stein EA, Paoletti R, et al.: Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003, 91:25–27.

    Article  CAS  Google Scholar 

  42. Ridker PM: Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003, 26:III39-III44.

    Article  PubMed  Google Scholar 

  43. Caslake MJ, Stewart G, Day SP, et al.: Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003, 171:245–253.

    Article  PubMed  CAS  Google Scholar 

  44. Sattar N, Gaw A, Scherbakova O, et al.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108:414–419.

    Article  PubMed  CAS  Google Scholar 

  45. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methyl-glutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712–1719.

    PubMed  CAS  Google Scholar 

  46. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391–397.

    Article  PubMed  Google Scholar 

  47. Festa A, D’Agostino R Jr, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42–47.

    PubMed  CAS  Google Scholar 

  48. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004, 109:2818–2825.

    Article  PubMed  CAS  Google Scholar 

  49. Balk EM, Lau J, Goudas LC, et al.: Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003, 139:670–682.

    PubMed  CAS  Google Scholar 

  50. Thompson PD, Buchner D, Pina IL, et al.: Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003, 107:3109–3116.

    Article  PubMed  Google Scholar 

  51. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology, Hartford Hospital, 80 Seymour Street, PO Box 5037, 06102-5037, Hartford, CT, USA

    Justin B. Lundbye MD & Paul D. Thompson MD

Authors
  1. Justin B. Lundbye MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul D. Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lundbye, J.B., Thompson, P.D. Statin use in the metabolic syndrome. Curr Atheroscler Rep 7, 17–21 (2005). https://doi.org/10.1007/s11883-005-0070-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-005-0070-9

Keywords

Search

Navigation